 |
424 Diseases |  |
807 Trials |
|
807 Trials |  |
14372 News |  |
| «12...222223224225226227228229230231232...235236» |
- ||||| Kevzara (sarilumab) / Asahi Kasei, Regeneron, Sanofi
New P2 trial: SARILNIUSATURN: Phase II Study to Analyze Sarilumab in Non-Infectious Uveitis (clinicaltrials.gov) - Jul 14, 2013
P2, N=57, Recruiting, Sponsor: Sanofi
- | Avastin (bevacizumab) / Roche
New P2 trial, Combination therapy, Metastases: Evaluation of Bevacizumab in Combination With First-Line Chemotherapy in Patients Aged 75 Years of Older With Metastatic Colorectal Adenocarcinoma (Prodige20) (clinicaltrials.gov) - Jul 14, 2013
P2, N=102, Recruiting, Sponsor: Centre Hospitalier Universitaire Dijon
- New P2 trial: Gemcitabine Hydrochloride, and Radiation Therapy in Patients With Borderline Resectable Pancreatic Cancer (clinicaltrials.gov) - Jul 10, 2013
P2, N=50, Recruiting, Sponsor: Albert Einstein College of Medicine of Yeshiva University
- | GVAX Pancreas (allogeneic GM-CSF-secreting tumor cells) / Novartis, Yervoy (ipilimumab) / BMS
New P2 trial, Combination therapy, Metastases: FOLFIRINOX Followed by Ipilimumab With Pancreatic Tumor Vaccine in Treatment of Metastatic Pancreatic Cancer (clinicaltrials.gov) - Jul 9, 2013
P2, N=92, Recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
- ||||| ipatasertib (RG7440) / Roche
New P2 trial, Combination therapy, Metastases: A Study of Ipatasertib (GDC-0068) in Combination With Fluoropyrimidine Plus Oxaliplatin in Participants With Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer (clinicaltrials.gov) - Jul 9, 2013
P2, N=120, Recruiting, Sponsor: Genentech
- |||| ipatasertib (RG7440) / Roche
Enrollment open, Combination therapy, Metastases: A Study of Ipatasertib (GDC-0068) in Combination With Fluoropyrimidine Plus Oxaliplatin in Participants With Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer (clinicaltrials.gov) - Jul 7, 2013
P2, N=120, Recruiting, Sponsor: Genentech
Not yet recruiting --> Recruiting
- Avastin (bevacizumab) / Roche
Enrollment open: BEV-ONCO: Study Comparing Pathological Responses Observed on Colorectal Cancer Metastases Resected After Preoperative Bevacizumab With FOLFOX or FOLFIRI. (clinicaltrials.gov) - Jul 4, 2013
P2, N=60, Recruiting, Sponsor: Cliniques universitaires Saint-Luc- Universit
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Enrollment change: P-HDFL-DI: Weekly Docetaxel/Irinotecan for Non-resectable Gastric Cancers After Cisplatin Plus 5-FU/Leucovorin (clinicaltrials.gov) - Jul 3, 2013
P2, N=29, Completed, Sponsor: National Taiwan University Hospital
Not yet recruiting --> Recruiting N=40 --> 29
- Trial completion: P-HDFL-DI: Weekly Docetaxel/Irinotecan for Non-resectable Gastric Cancers After Cisplatin Plus 5-FU/Leucovorin (clinicaltrials.gov) - Jul 3, 2013
P2, N=29, Completed, Sponsor: National Taiwan University Hospital
N=40 --> 29 Recruiting --> Completed
- | Kinselby (resminostat) / 4SC, Yakult Honsha
Enrollment closed, Combination therapy, Metastases: SHORE: 4SC-201 (Resminostat) in Advanced Colorectal Carcinoma (clinicaltrials.gov) - Jul 2, 2013
P1/2, N=17, Active, not recruiting, Sponsor: 4SC AG
Recruiting --> Completed Recruiting --> Active, not recruiting
- Recentin (cediranib) / AstraZeneca
Enrollment closed: Cediranib Maleate and Combination Chemotherapy in Treating Patients With Advanced Biliary Cancers (clinicaltrials.gov) - Jun 30, 2013
P2, N=36, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Suspended --> Active, not recruiting
- | Avastin (bevacizumab) / Roche
Trial completion, Surgery: NSABP C-08: Fluorouracil, Leucovorin, and Oxaliplatin With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II or Stage III Colon Cancer (clinicaltrials.gov) - Jun 30, 2013
P3, N=2632, Completed, Sponsor: National Cancer Institute (NCI)
Suspended --> Active, not recruiting Active, not recruiting --> Completed
- PF-04136309 / Pfizer
Enrollment change, Metastases: FOLFIRINOX Plus PF-04136309 in Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma (clinicaltrials.gov) - Jun 27, 2013
P1, N=44, Recruiting, Sponsor: Washington University School of Medicine
Active, not recruiting --> Completed N=56 --> 44
- bortezomib / Generic mfg.
Enrollment change, Combination therapy: AALL07P1: Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma (clinicaltrials.gov) - Jun 27, 2013
P2, N=60, Suspended, Sponsor: National Cancer Institute (NCI)
N=56 --> 44 N=150 --> 60
- ||||| Zaltrap (ziv-aflibercept IV) / Sanofi
New P2 trial, Metastases: Safety and Effectiveness Study of Chemotherapy and Ziv-aflibercept to Treat Metastatic Colorectal Cancer (clinicaltrials.gov) - Jun 26, 2013
P2, N=120, Not yet recruiting, Sponsor: National Surgical Adjuvant Breast and Bowel Project (NSABP)
- New P2 trial, Metastases: Molecularly Tailored Therapy for Pancreas Cancer (clinicaltrials.gov) - Jun 26, 2013
P2, N=20, Recruiting, Sponsor: Georgetown University
- | Zolinza (vorinostat) / Merck (MSD)
Trial completion, Metastases: Vorinostat, Irinotecan, Fluorouracil, and Leucovorin in Treating Patients With Advanced Upper Gastrointestinal Cancer (clinicaltrials.gov) - Jun 25, 2013
P1, N=23, Completed, Sponsor: Roswell Park Cancer Institute
N=150 --> 60 Active, not recruiting --> Completed
- |||| Avastin (bevacizumab) / Roche
Enrollment open, Combination therapy, Metastases: CHARTA: Efficacy of FOLFOX+Bevacizumab in Combination With Irinotecan in the Treatment of Metastatic Colorectal Cancer (clinicaltrials.gov) - Jun 24, 2013
P2, N=250, Recruiting, Sponsor: Martin-Luther-Universit
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- ||||| Zaltrap (ziv-aflibercept IV) / Sanofi
New P2 trial, Combination therapy, Metastases: A Study of Aflibercept in Combination With FOLFIRI in Patients With Second-Line Metastatic Colorectal Cancer in Japan (clinicaltrials.gov) - Jun 18, 2013
P2, N=60, Active, not recruiting, Sponsor: Sanofi
- || Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly
New P3 trial: ITACa: Sequential Treatment Strategy for Metastatic Colorectal Cancer (clinicaltrials.gov) - Jun 13, 2013
P3, N=350, Recruiting, Sponsor: Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
- | Avastin (bevacizumab) / Roche
Enrollment change, Metastases: PRODIGE 9: Combination Chemotherapy and Bevacizumab With or Without Bevacizumab Maintenance Therapy in Treating Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Jun 12, 2013
P3, N=492, Active, not recruiting, Sponsor: Federation Francophone de Cancerologie Digestive
Not yet recruiting --> Recruiting N=188 --> 492
- Trial completion, Combination therapy, Metastases: Bortezomib, Fluorouracil, Leucovorin, and Oxaliplatin in Treating Patients With Advanced or Metastatic Colorectal Cancer (clinicaltrials.gov) - Jun 10, 2013
P1, N=16, Completed, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
N=188 --> 492 Active, not recruiting --> Completed
- | prednisone / Generic mfg.
Trial completion: Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jun 10, 2013
P3, N=392, Completed, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||| Neupogen (filgrastim) / Kyowa Kirin, Amgen
Enrollment closed, IO biomarker, Surgery: acns0333: Combination Chemotherapy, Radiation Therapy, and an Autologous Peripheral Blood Stem Cell Transplant in Treating Young Patients With Atypical Teratoid/Rhabdoid Tumor of the Central Nervous System (clinicaltrials.gov) - Jun 9, 2013
P3, N=70, Active, not recruiting, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- zoledronic acid / Generic mfg.
Enrollment change, Metastases: Zoledronic Acid and Combination Chemotherapy in Treating Patients With Newly Diagnosed Metastatic Osteosarcoma (clinicaltrials.gov) - Jun 4, 2013
P=N/A, N=24, Completed, Sponsor: Children's Oncology Group
Recruiting --> Active, not recruiting N=30 --> 24
- Avastin (bevacizumab) / Roche
New P2 trial, Surgery: Bevacizumab, Fluorouracil, Leucovorin Calcium, and Oxaliplatin Before Surgery in Treating Patients With Stage II-III Rectal Cancer (clinicaltrials.gov) - Jun 4, 2013
P2, N=43, Recruiting, Sponsor: University of Southern California
- ||||||| Solu-Cortef (hydrocortisone sodium succinate injection) / Pfizer
Trial completion: T-Cell #4: Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia or Advanced Lymphoblastic Non-Hodgkin's Lymphoma (clinicaltrials.gov) - Jun 3, 2013
P3, N=573, Completed, Sponsor: Children's Oncology Group
N=30 --> 24 Active, not recruiting --> Completed
- ||||| Erbitux (cetuximab) / Eli Lilly
New P2 trial, Metastases: Nordic 8 - A Phase II Trial (clinicaltrials.gov) - Jun 2, 2013
P2, N=180, Recruiting, Sponsor: Per Pfeiffer
- | New P2 trial, Metastases: A Phase II Study of Locally Advanced Pancreatic Cancer (clinicaltrials.gov) - Jun 2, 2013
P2, N=86, Enrolling by invitation, Sponsor: National Health Research Institutes, Taiwan
- |||| efatutazone (CS-7017) / Daiichi Sankyo
Trial completion, Combination therapy, Metastases: Study of CS-7017 in Combination With FOLFIRI in Subjects With Metastatic Colorectal Cancer Who Failed First-Line Therapy (clinicaltrials.gov) - May 28, 2013
P2, N=100, Completed, Sponsor: Daiichi Sankyo Inc.
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Avastin (bevacizumab) / Roche
Trial withdrawal: PERIMAX: Perioperative Treatment of Resectable Liver Metastases (clinicaltrials.gov) - May 27, 2013
P2, N=0, Withdrawn, Sponsor: University of Regensburg
Active, not recruiting --> Completed Recruiting --> Withdrawn
- Avastin (bevacizumab) / Roche
Enrollment change: PERIMAX: Perioperative Treatment of Resectable Liver Metastases (clinicaltrials.gov) - May 27, 2013
P2, N=0, Withdrawn, Sponsor: University of Regensburg
Recruiting --> Withdrawn N=130 --> 0
- Avastin (bevacizumab) / Roche
Enrollment change, Combination therapy, Metastases: A Study of Avastin (Bevacizumab) in Combination With mFOLFOX6 in Treatment-Na (clinicaltrials.gov) - May 22, 2013
P3, N=0, Withdrawn, Sponsor: Hoffmann-La Roche
N=130 --> 0 N=825 --> 0
- sapitinib (AZD8931) / AstraZeneca
New P1/2 trial, Combination therapy: PANTHER: Phase I/II Trial of Antagonism of HER in GI Cancer (clinicaltrials.gov) - May 22, 2013
P1/2, N=24, Not yet recruiting, Sponsor: University College, London
- |||| Avastin (bevacizumab) / Roche
Trial completion, Metastases: A Study of Avastin (Bevacizumab) With XELOX or FOLFOX in Patients With Metastatic Colorectal Cancer and Disease Progression Under First-line FOLFIRI and Avastin (clinicaltrials.gov) - May 22, 2013
P2, N=76, Completed, Sponsor: Hoffmann-La Roche
N=825 --> 0 Active, not recruiting --> Completed
- ||||| thioguanine / Generic mfg.
Enrollment change: AALL0331: Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia (clinicaltrials.gov) - May 21, 2013
P3, N=5377, Active, not recruiting, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed N=3381 --> 5377
- | Erbitux (cetuximab) / Eli Lilly
New P2 trial: Study Comparing Pathological Responses Observed on Colorectal Cancer Metastases Resected After Preoperative Treatment Combining Cetuximab With FOLFOX or FOLFIRI in RAS and B-RAF WT Tumors (clinicaltrials.gov) - May 19, 2013
P2, N=60, Recruiting, Sponsor: Cliniques universitaires Saint-Luc- Universit
- | Avastin (bevacizumab) / Roche
New P2 trial: BEV-ONCO: Study Comparing Pathological Responses Observed on Colorectal Cancer Metastases Resected After Preoperative Bevacizumab With FOLFOX or FOLFIRI. (clinicaltrials.gov) - May 19, 2013
P2, N=60, Recruiting, Sponsor: Cliniques universitaires Saint-Luc- Universit
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., cisplatin / Generic mfg.
Trial completion: Radiation Therapy + Combination Chemotherapy as 1st-Line Therapy for Patients With Inoperable Esophageal Cancer (clinicaltrials.gov) - May 14, 2013
P2/3, N=266, Completed, Sponsor: UNICANCER
N=3381 --> 5377 Recruiting --> Completed
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly
Trial completion: Phase II Trial of FOLFOX6, Bevacizumab and Cetuximab in Patients With Colorectal Cancer (clinicaltrials.gov) - May 14, 2013
P2, N=67, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed Active, not recruiting --> Completed
- | Avastin (bevacizumab) / Roche
New P2 trial, Metastases: First-line Irinotecan, Lederfolin and 5FU (FOLFIRI) and Bevacizumab in Patients With Advanced Colorectal Cancer (clinicaltrials.gov) - May 13, 2013
P2, N=75, Not yet recruiting, Sponsor: Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente
- erlotinib / Generic mfg.
Enrollment closed, Metastases: Erlotinib and Chemotherapy for 2nd Line Treatment (Tx) of Metastatic Colorectal Cancer (mCRC) (clinicaltrials.gov) - May 13, 2013
P2, N=70, Active, not recruiting, Sponsor: OHSU Knight Cancer Institute
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- |||| Erbitux (cetuximab) / Eli Lilly
Trial completion, Metastases: FUTURE: Study to Evaluate the Efficacy and Safety of FOLFOX-4 Plus Cetuximab Versus UFOX Plus Cetuximab. (clinicaltrials.gov) - May 13, 2013
P2, N=302, Completed, Sponsor: Merck KGaA
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
New P2 trial, Metastases: A Phase II Trial of Perioperative Chemotherapy With Oxaliplatin, 5-Fluorouracil, Leucovorin(MODIFIED FOLFOX6) in Patients With Locally Advanced Operable Gastric Cancer (clinicaltrials.gov) - May 9, 2013
P2, N=52, Completed, Sponsor: Seoul National University Hospital
- Enrollment change, Combination therapy, Metastases: Phase I Trial of Sorafenib + FOLFIRI In Metastatic Colorectal Cancer (clinicaltrials.gov) - May 8, 2013
P1, N=16, Completed, Sponsor: Ottawa Hospital Research Institute
Active, not recruiting --> Completed N=30 --> 16
- ||| Fotivda (tivozanib) / Kyowa Kirin, LG Chem
Enrollment closed, Combination therapy, Metastases: A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy (clinicaltrials.gov) - May 8, 2013
P2, N=265, Active, not recruiting, Sponsor: Astellas Pharma Inc
N=30 --> 16 Recruiting --> Active, not recruiting
- | Trial completion, Combination therapy, Metastases: Phase I Trial of Sorafenib + FOLFIRI In Metastatic Colorectal Cancer (clinicaltrials.gov) - May 8, 2013
P1, N=16, Completed, Sponsor: Ottawa Hospital Research Institute
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- |||| oxaliplatin / Generic mfg., sorafenib / Generic mfg.
Trial completion, Combination therapy, Metastases: Study of Modified FOLFOX6 Plus or Minus Sorafenib in Stage IV Metastatic Colorectal Carcinoma (mCRC) Subjects (clinicaltrials.gov) - May 6, 2013
P2, N=198, Completed, Sponsor: Bayer
Active, not recruiting --> Completed Active, not recruiting --> Completed
- imatinib / Generic mfg.
Trial initiation date: AALL01P2: Combination Chemotherapy and Imatinib Mesylate in Treating Children With Relapsed Acute Lymphoblastic Leukemia (clinicaltrials.gov) - May 5, 2013
P=N/A, N=126, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Initiation date: Sep 2001 --> Jan 2003
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly
Enrollment open: ATOM: Achievement of Improved Survival by Molecular Targeted Chemotherapy and Liver Resection for Not Optimally Resectable Colorectal Liver Metastases (clinicaltrials.gov) - May 5, 2013
P2, N=180, Recruiting, Sponsor: EPS Corporation
Initiation date: Sep 2001 --> Jan 2003 Not yet recruiting --> Recruiting